OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS

• US 20090258933A1
• Filed: 06/17/2009
• Published: 10/15/2009
• Est. Priority Date: 06/20/2000
• Status: Abandoned Application

• Current Assignee: National Cancer Center
• Original Assignee: Dainippon Pharmaceutical Co., Ltd. (Sumitomo Chemical Company Limited)
• Inventors: Ochiya, Takahiro, Furuse, Masayasu, Itoh, Hiroshi, Sano, Akihiko, Nagahara, Shunji, Terada, Masaaki, KUBOTA, Shunichiro
• Application Number:
  US12/486,703
• Publication Number:
  US 20090258933A1
• Time in Patent Office: Days
• US Class Current: 514/44.R
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/2063 Proteins, e.g. gelatin
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided.

Claims

1-11. -11. (canceled)

12. A method of inhibiting expression of a target mRNA in a subject comprising:

administering to the subject an article comprising an oligonucleotide of 5 to 30 nucleotides in length and a water soluble atelocollagen that has a degree of cross-linking of 3 or less.

13. The method of claim 12, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

14. The method of claim 12, in which the atelocollagen is a water soluble type I atelocollagen.

15. The method of claim 12, in which the oligonucleotide has at least one phosphorothioate bond.

16. The method of claim 12, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

17. The method of claim 12, in which the oligonucleotide is a DNA or a DNA derivative.

18. The method of claim 12, in which the oligonucleotide is a RNA or a RNA derivative.

19. A method of inhibiting expression of a target mRNA in a cell comprising:

contacting the cell with an article comprising an oligonucleotide of 5 to 30 nucleotides in length and a water soluble atelocollagen that has a degree of cross-linking of 3 or less.

20. The method of claim 19, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

21. The method of claim 19, in which the atelocollagen is a water soluble type I atelocollagen.

22. The method of claim 19, in which the oligonucleotide has at least one phosphorothioate bond.

23. The method of claim 19, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

24. The method of claim 19, in which the oligonucleotide is a DNA or a DNA derivative.

25. The method of claim 19, in which the oligonucleotide is a RNA or a RNA derivative.